Logical Therapeutics raises $17 million

Logical Therapeutics has announced that it has closed its $16.9 million fundraising round, with SV Life Sciences leading a group that includes Burrill & Company, Novo A/S, and Novitas Capital. The company is developing NSAID drugs. LT-NS001, its lead therapy, is in a Phase IIb/III study. The funds should get the developer to the registration stage, but it will seek a partner to launch the therapy.